Laurus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LAURUS
LAURUS has twenty-one approved drugs.
There are eight tentative approvals on LAURUS drugs.
Summary for Laurus
| US Patents: | 0 |
| Tradenames: | 17 |
| Ingredients: | 17 |
| NDAs: | 21 |
| Patent Litigation for Laurus: | See patent lawsuits for Laurus |
Drugs and US Patents for Laurus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laurus | ATAZANAVIR SULFATE | atazanavir sulfate | CAPSULE;ORAL | 212579-002 | Apr 30, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | VALSARTAN | valsartan | TABLET;ORAL | 218897-003 | Apr 21, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | VALSARTAN | valsartan | TABLET;ORAL | 218897-001 | Apr 21, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | PIRFENIDONE | pirfenidone | CAPSULE;ORAL | 212724-001 | Jul 19, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
